ClinicalTrials.gg
RecruitingNCT07606950Updated Nov 12, 2026

Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

A Phase 3 interventional study of HRS-5635 Injection and Placebo in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 12, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
35th of 273
540 · median 120
Started
2026
with 26 others
Phase 3
26 of 375
5 open now
Primary completion
2028-06
later than 91 of 109 live
Registered
359th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 35th largest by planned enrollment of the 273 interventional ones that give a count, is one of 27 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 91 of the 109 other live ones, and was the 359th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

83 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.

03

Conditions studied

  • Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic defined as HBV infection documented for at least 6 months prior to screening;
  2. Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation;
  3. HBeAg negative at screening;
  4. On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 4 weeks before randomization;
  5. Need to take effective measures;
  6. Volunteer to sign an .

Exclusion criteria

Exclusion Criteria:

  1. History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic that may affect the evaluation of the study;
  2. With disease;
  3. History of solid organ transplantation or hematopoietic stem cell transplantation;
  4. and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases;
  5. Malignant tumors were diagnosed within 5 years prior to randomization;
  6. Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results;
  7. Laboratory tests during the screening period were obviously abnormal;
  8. Prolonged or other clinically significant abnormal results that may pose a significant safety risk to the subject during the screening period;
  9. History of drug use, alcohol or drug abuse in the 12 months prior to randomization;
  10. Participated in clinical study of other drugs (received experimental drugs);
  11. Pregnant or nursing women;
  12. Allergic to a drug ingredient or component;
  13. Other reasons for ineligibility as judged by the investigators.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    HRS-5635 Injection

    Drug: HRS-5635 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • HRS-5635 Injection, administered by subcutaneous injection;

  • DrugPlacebo

    Placebo, administered by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with sustained HBV DNA suppression and HBsAg loss within 24 weeks after discontinuation of all HBV therapy

    Time frame: 24 weeks after discontinuation of all CHB treatment

Secondary outcomes

  1. Percentage of participants with sustained HBV DNA suppression and HBsAg < 100 IU/mL

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  2. Percentage of participants with sustained HBV DNA suppression and HBsAg < 10 IU/mL

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  3. Percentage of participants with sustained HBV DNA suppression

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  4. Percentage of participants with HBsAg < 100 IU/mL

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  5. Percentage of participants with HBsAg < 10 IU/mL

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  6. Changes from baseline in mean log10 HBsAg levels

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  7. Percentage of participants with HBsAg loss

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  8. Percentage of participants with HBsAg seroconversion

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  9. Percentage of participants with HBeAb positive

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  10. Percentage of participants with virologic breakthrough

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  11. Percentage of participants with drug resistance

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

  12. Percentage of participants who meet the criteria for stopping nucleos(t)ide analogue (NA) therapy

    Time frame: Week 72 and Week 96

  13. Relapse rate after discontinuation of NAs therapy

    Time frame: Up to 24 weeks after discontinuation of NAs treatment

  14. Treatment-emergent adverse events

    Time frame: Up to 24 weeks after discontinuation of NAs treatment

  15. Percentage of participants with detectable anti-drug antibodies

    Time frame: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment

07

Study locations

1 of 1 sites recruiting
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangzhou 510515, China
    Recruiting
    • Jinlin Hou · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
May 26, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: x•••@hengrui.com · •••2973→m•••@hengrui.com · •••2973. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Contact Study contact changed: x•••@hengrui.com · •••2973→m•••@hengrui.com · •••2973. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07606950
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jul 17, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Yi Lu
Contact
minghao.lyu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5635

Start the discussion